micro parts to market... faster

Combination inhalers

082615     Combination inhalers for upper airway diseases – oral inhalers containing two drugs that compliment the therapeutic actions of one another – have seen a significant increase in development activity and product proliferation in the past five years. This growth is due to improved patient experience from improved ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are showing significant commercial success in the two markets for which they are indicated – Asthma and COPD – both of which are forecast to grow at impressive rates for the remainder of the decade.

In the area of inhaler technology, MES has the exclusive worldwide rights to sell one of the most innovative DPIs available today, the DoseOne™ Single Dose Powder Inhaler. Development of the DoseOne™ single dose powder inhaler (US Patent #7,832,399 B2 and #8,360,057 B2) required a multi-disciplinary team approach, as any such drug delivery device needs to combine not just design skills, but also software and mechanical engineering capabilities, and expertise in analytical science and industrialisation. MES worked on the DoseOne™ device from concept creation, allowing the design to be sympathetic to the requirements for mass manufacture and regulatory compliance.

The DoseOne™ is equipped with a simple dose readiness indicator and a dose delivery indicator — which means it conforms with strict FDA patient-compliance regulations previously only attained by expensive MDIs and multi-use DPIs. DoseOne™  is a perfect example of what can be achieved if an innate understanding of micro manufacturing design and manufacturing is combined with an understanding of the regulatory environment that exists around drug delivery devices these days, and a realisation of the potential for innovative solutions that cater for mass “self” administration of drugs in a cost effective and safe way.

If you are a pharma manufacturer out there looking to locate a novel, cost-effective, and efficient drug delivery option, please email Donna Bibber at donna@microengineeringsolutions.com. For full details of DoseOne™ see www.dose-one.com.

Micro Medical Device Components

8/19/15     Micro components continue to shrink in size demanding ever greater precision and improved handling of parts with sub-micron-sized features. New approaches in micro-machining technology include higher precision systems from traditional micro-machining developers, as well as techniques using additive manufacturing processes semiconductor wafer scale technology on the smallest of micro-parts. With micro-machining in molding techniques, manufacturers can create an astounding array of extremely small parts for medical uses including catheters, surgical tools, and implants made from a variety of materials including metals, ceramics, silicon and PEEK polymers. Micro components also increasingly power the latest high-tech devices with the small batteries, connectors, LEDs and IC chips found in smartphones and iPads, and some of the tiny devices being used in aerospace and defense applications by the military.

“The industry is definitely getting smaller and smaller, in terms of the size of the component, and the precision of the components they require. We are approaching micro in feature size and tolerance, and the envelope is being pushed further in that direction every day,” said Donna Bibber, president and CEO of Micro Engineering Solutions (MES Charlton City, MA), a manufacturer and developer of micro-machined and micro-molded parts.

As micro components become smaller and more precise, manufacturers face more difficulties in combining materials, which can be either metal or plastic pieces, to make an assembly, Bibber noted. Problems can also arise in measuring and testing sub-micron parts. ”The testing and the metrology is as important as anything,” she added. “You probably heard the saying ‘You can’t make it if you can’t measure it.” At this level of small, that is even more important.”

A recent MES project involved making an endoscope measuring 5mm in diameter by 20mm long in which there are 18 different metal components working together, so the endoscope can move and rotate a needle 360 degrees, Bibber recalled. “You can imagine how much of the stack up tolerance, literally microns, in this instance,” she said. “We can’t always scale up to the tolerance needed from machined parts to molded parts, but we have a plan for scale up from part one in terms of stack up tolerances.”

Another major issue is the trend toward more challenging part geometries. “The trends are small features, small parts, and small assemblies,” Bibber said. “The challenges are mostly in handling, and metrology. The bulk of the cost of the assemblies are really in how you handled the components, and how they are measured.”

Micro Ophthalmic Ocular Implants

More often than not, the smallest component in a medical or pharmaceutical implant or device is the enabling component.  Micro manufacturing (micro injection molding, micro machining, and micro automation) has blazed the trail for many new developments, implants, micro surgery, and robotic surgeries today.  We will explore one such market segment of which micro manufacturing has played and continues to plan a significant role in worldwide growth in the next five years…..Ophthalmic devices.

Age related eye diseases such as cataracts, diabetic retinopathy, glaucoma and macular degeneration (to name a few) continue to cause loss of vision either significantly or completely. Driven by a baby boomer aging population, technology innovations and vastly emerging markets in China and India, the ophthalmic devices sector is expected to attain a double-digit growth. Ophthalmic and intraocular implants are largely made up of many micro sized and highly precise components and assemblies.  This market sector continues to remain one of the largest and fastest growing micro medical and pharma micro device sectors, globally.

The global ophthalmic device market was valued at $10 Billion in 2008 with the US market comprising $5.5 Billion of this. Driven by growth in the vision care and cataract surgery market categories, the market is forecast to grow by 8.5% annually during 2008-2015 to reach $15 Billion U.S. ($9.8 Billion in the US).

On the downside, due to reduced consumer discretionary spending in the U.S., the market continues to grapple with growth decline in the refractive surgery. On the upside, the treatments for other conditions are the major factors for the vastly emerging growth markets worldwide.

• Major players in the pharmaceutical space include
o Alcon (now part of Novartis),
o Allergan, Inc.,
o Bausch & Lomb Incorporated,
o Daiichi Pharmaceutical Co., Ltd.,
o Genentech Inc.
o Inspire Pharmaceuticals Inc.,
o ISTA Pharmaceuticals Inc.,
o Johnson & Johnson (Vistakon Pharmaceuticals, LLC)
o Merck & Co., Inc
o Pfizer, Inc.,
o Santen Pharmaceutical Co., Ltd.

• Major players in the surgical space include
o Abbott Medical Optics
o Alcon (now part of Novartis)
o Bausch & Lomb
The eye is a complex and sensitive organ.  There are many structures and targets, located closely together and sometimes, in terms of target for treatment, these structures are conflicting one another in their proximity.  Existing in the eye are significant defense mechanisms, such as the tear film and the cornea, that present challenges for medication to enter.  Specifically, the vitreous fluid is difficult for injected medication to traverse to reach the posterior of eye.

micro eye
Anatomy of Human Eye, Photo credit- MasterEyeAssociates.com


A number of CONDITIONS of varying seriousness and interest
1. Glaucoma
2. Cataracts
3. Diabetic retinopathy
4. Age-related macular degeneration
5. Dry eye syndrome
6. Uveitis
7. Retinal detachment
8. Advanced Age & Lifestyle Diseases; still an extremely high level of unmet need
9. Other (Of lesser importance can be treated / managed with eye glasses, OTC medication, antibiotics, and specific hygiene protocols and, in limited instances, with surgery)

TREATMENT often requires contributions from two or more parts of an inseparable therapeutic triad
• Ophthalmic pharmacology
• Surgery of the visual tract
• Implantable ophthalmic medical devices

Highly innovative specialist companies dominate pharmacological development. Innovative companies on the drug delivery side are equally important. Industrial development occurs through a large number of highly focused, research driven specialist companies, often very small and funded through innovative-support funding programs. Such companies need to be able to easily find a large marketing partner such as big pharma, which is often funding this development externally in lieu of doing it themselves in-house.

Highly innovative specialty companies define and epitomize the requirement for treatments of these conditions with micro sized and ultra-precision components and assemblies.  Anyone who has ever worn corrective contacts and/or been on the bad end of a windy day near an outdoor fire pit, you have probably noticed that the smallest speck in your eye can cause you severe pain.  The reasons for intraocular implants being micro-sized then are to provide the eye an extreme level of comfort with the least invasive, yet compliant implants in the human body.  The thin and delicate structures of the eye require paper thin and flexible components that are nonetheless strong enough to withstand extreme fluid pressures in and behind the eye. The successful creation of a device that is both paper thin and strong is an engineering challenge that requires the skill and expertise that only micro molding and nano surface specialty companies can understand and implement.  Let us explore this micro requirement specifically for some of the more common conditions/treatments.

For example, Glaucoma, the “sneak thief of sight” affects many elderly, African Americans, and those with a family history.  Considered the 2nd leading cause of blindness (after cataracts), Glaucoma is principally caused by elevated intraocular pressure within the eye.  Micro surgical devices and intraocular implants are used if eye drops are not an effective treatment.  Micro components and surgical treatments include:
o Trabeculectomy (laser surgery) is most common approach; creates a hole in sclera to allow fluid to drain into the outer cyst
o Conventional surgery can also be used to create a drainage hole in the white part of the eye if laser surgery is unsuccessful
o Implant surgery positions a device to aid the drainage; estimated that several thousand are performed each year in US
o Canaloplasty places a microcatheter into Canal of Schlemm to enlarge the natural drainage channel for healthy eyes

The below image shows a glaucoma drain, commonly known as a shunt.  This shunt is injection molded, spherically shaped with a wedge-shaped radial side action in the tool that creates the drain geometry.  At the end of the side action travel is a 250 micron orifice whereby no flash can be tolerated.  Shunts are mostly tubular, however this one is 3d shaped and designed for placement in the sclera (side of the eye).  It is designed to act like a venturi system which uses the pressure of the eye to push the discharge from glaucoma to behind the eye where it can drain.  In addition to the 250 micron entry orifice, there are 4 suture holes of 250 micron diameter (2x a human hair) molded into the top of the implant.  These suture holes also must be free and clear of particulate or flash to prevent sutures from cutting during implantable or after surgery.

micro glaucoma drain
Micro Injection Molded Glaucoma Drain (Shunt), Photo Courtesy of Micro Engineering Solutions
Age Related Macular Degeneration (AMD) is the leading cause of permanent impairment of reading ability and loss of fine detail for those over age 65.  The macula is the central portion of the retina used for seeing fine detail and can be destroyed in one of two ways beginning at age 60. In 2004, 1.5% of adults over age 40 experience advanced AMD and 6.1% had intermediate AMD (1.8 and 7.3 million adults, respectively). The dry form is the most common form of AMD but it can become the wet form which is more destructive. In dry AMD light sensitive cells in macula break down. Dry AMD is treated with oral ingestion with a high dose of anti-oxidants and zinc. Wet AMD is characterized by growth of abnormal blood vessels behind the retina. Laser surgery used in a small % of patients to destroy vessels but the treatment also damages the retina. Another treatment approach involves intravenous injection of a photo activated drug into the arm. When exposed to light in the eye the drug is activated and it destroys the new unwanted blood vessels. Injections into the eye to block the growth of abnormal new blood vessels is also available. Prior to 2007, medicine was not available to treat AMD; in 2007 the market was estimated to represent more than $1.2 billion in sales.

The image below shows an AMD guidance device used in laser surgery.  The spherical radius sits on the cornea and the lens underside must be free of flash, mold parting lines, and surface imperfections.  The 300 micron laser hole shuts off on the spherical radius and blending these geometries three-dimensionally in steel to produce the polymer micro injection molded component is very challenging.

In this case, material selection was also a key factor in providing the rigidity required to hold the guide in place during laser deployment.  USP Class VI materials (they have previously been used in medical products) are necessary and also require OEM testing even if they are shown to be Class VI compliant.

Macular Degeneration Laser Guide, Photo Courtesy of Micro Engineering Solutions
Dry Eye is one of the most common reasons for an appointment with an ophthalmologist.  Dry Eye condition is defined as an irritation of the eye due to an inability to produce or maintain/retain enough tears on the surface of the eye.  It can result in damage to the front surface of the eye and impair vision.  The causes vary from specific diseases (such as Sjögren’s syndrome or lacrimal and meibomian gland dysfunction) to other causes including age, gender (women are more susceptible), medications, certain medical conditions, environmental conditions such as exposure to smoke, wind, or dry climates, and other factors such as prolonged use of contact lenses or refractive eye surgeries (LASIK).

Treatment, may require micro components (approximately ¼ the size of a grain of rice) include punctal plugs whereby a plug is surgically placed in both the top and lower eyelid to prevent fluid in the eye from draining, thereby keeping the eye hydrated.   Additional treatments use OTC eye drops or prescription lubricants and anti-inflammatories. These medications are extremely costly and if not administered properly (balancing the dropper over the eye and making sure it all gets into the eye) defeats the purpose and wastes consumer and healthcare costs.  Much effort is put into micro pumping and micro administering of these fluids with aspirators, implantable pumps, and slow release polymers that release the drug in timed increments.

micro plug
Punctal plugs placed in drainage channels of the upper and lower eyelids. Photo credit- allaboutvision.com

Design Considerations
Many drug delivery devices are now manufactured in non-traditional ways such as silicon wafer technology, MEMS, and ground-up manufacturing methods.  These methods are then matched to more traditional top down methods to provide medical and pharmaceutical companies with differentiated and strategic value.  These processing techniques are typically developed using “conventional” single micron level positional accuracy using current work holding devices.  These methods are inadequate in preventing cross contamination of actives in capillaries and other microscopic microfluidic assemblies.
NANOmeter-positional accuracy was not available to the mainstream even 2-3 years ago.  Even today, traditional pallet-holders coupled with automatic X, Y, Z probing can barely guarantee a 1 MICRON positional accuracy.  It is also strange to think this isn’t good enough for the eye, but the surface finish is absolutely necessary, orders of magnitude tighter tolerances than seen in conventional or macro manufacturing.
So it is evident that developing ophthalmic and intraocular implants require thinking at the scale of which the human body operates and the human body operates at the scale of nanometers.  White and Red blood cells on average range from 8-100 microns in diameter and DNA can be as small as 2-3 NANOmeters.  In between these two range a great deal of discovery and science that we cannot begin to understand without simulation outside the body and mimicking strands of DNA and blood cells working together.  It is for this reason that ophthalmic, intraocular, drug delivery and pharmaceutical device companies are looking for help from manufacturers to push the boundaries of what is possible to achieve features and tolerances in the NANOmeter range.  What we have discovered in the micron range has certainly helped us to learn some top down methods that didn’t work and some bottom up methods that worked but needed some refinement using a combined top down/bottom up method.


Top Down Methods                                                  Bottom Up Methods

Laser Machining                                                                Genetic Code

EDM-WEDM                                                                      Complexity Theory

Ultrasonic Machining                                                       Self Assembly

Ion Machining                                                                    Biological Cell

Grinding                                                                               Proteins

CNC Machining                                                                  DNA and RNA

Chemical Milling                                                                LIGA

Photochemical Milling                                                      3D Printing

Electrochemical Machining

The above are MES Micro and Nano Manufacturing Methods used today and in the future.

Growing structures (ie. Bottom Up methods) to create geometry was also not mainstream until 2-3 years ago.  A good rule of thumb for material and process marrying will force a top down methodology until we can mill, grind, edm (electrical discharge machine), diamond turn, and etch no more. We have already used LIGA (German acronym meaning lithography, electroplating and molding) for many years as a Bottom Up method. However with the emergence of 3D printing, at some point in the near future, we will be looking at that technology to create geometry, surfaces, and – when the materials are available and 3D printable – human organs.  This will push micro manufacturers and macro manufacturers beyond our capabilities in Top-Down Methods OR there might be a “marriage made in heaven” employing both methods.

For example, in the area of diabetes, Google is developing a smart contact lense for measuring glucose in tears. Google says the lens comprises “chips and sensors so small they look like bits of glitter, and an antenna thinner than a human hair”. The chip and sensor are imbedded between two layers of soft contact lens material. A tiny pinhole in the lens allow tear fluid from the surface of the eye to seep into the glucose sensor. The prototype currently being tested can take glucose level readings every second. The project was cofounded by Brian Otis and Babak Parviz who worked together at the University of Washington before moving to Google. One can’t help imagine that, beyond diagnostics, completely encased electronics placed onto the cornea may one day bring vision, gaming, web browsing, and social interaction to a completely new level.
Alternative methods are coupling neuroscience with ophthalmic science as seen in Figure 1.7, which shows a retinal implant embedded in the eye that restores vision to the vision impaired or the visionless.

micro ophthalmic

Google Smart Contact Lens, photo courtesy of Google.
Non-traditional methods for manufacturing such as nanometer positional accuracy and dust-specked sized injection molded, machined, and assembled components are spawning technological advances in ophthalmic intraocular implants and intraocular drug delivery devices.  These new methods combine traditional top down methods and futuristic bottom up methods to provide medical and pharmaceutical device companies with enabling products to treat the likes of glaucoma, macular degeneration, cataracts, dry eye, and even diabetes around the world.
Areas unknown can be explored with micro manufacturing- restoring lost vision, enhancing vision, hydrating eyes in harsh conditions, gaining less invasive ways to cross the elusive blood-retinal barrier, micro-electronics and eyes controlling the brain to control prosthetics, and even controlling motion for paraplegics.  Imagine- the technology allowing people to see……people they haven’t seen in years, objects in a room, light in a sky, food on a plate, and to recognize a smile.  We are fortunate to be well positioned in micro and nano manufacturing to play a part in enabling these treatments and products that contribute to worldwide health.

New Micro Drug Delivery Technologies

8/5/15     Nowadays drug delivery and micro devices go hand in hand. Research is currently being done to delivery drugs directly to a problem area without the drug having to move through the entire body to hopefully get to its intended target.
Researchers at MIT have created a 3mm long device, that can hold 16 different drugs or drug cocktails, that can be implanted directly into tumors in lab mice. The device then releases the drugs into the cancerous tissues. After 24hrs the research analysis showed that the local drug response was similar to what occurs after systemic injection (drugs taken by mouth or injection that have to travel through the entire body to treat an issue).
Doing similar research, scientists at the Fred Hutchinson Cancer Research Center found a device could accurately predict systemic responses to drugs. This would enable the placement of multiple columns of drugs for analysis directly into a tumor, making it possible to assess drug effects with multiple biomarkers and in multiple regions to capture the heterogeneity of response within the tumor. This technology intentionally bypasses biodistribution, metabolism, bioavailability and excretion tissues associated with systemic dosing, making it possible to focus on whether the drug engages its target, how cancer cells respond to target engagement and whether the fate of the exposed cells indicates potential for a patient response.
By making micro sized devices that can be sent to a specific are of the body so that the drugs can be released in a controlled manner, revolutionizes how we treat ailments nowadays. The entire body isn’t being affected by the strong drugs, just the target area is being affected. This is cutting edge technology that we have been in the midst of researching and developing. It is changing the way we treat people, in a positive manner.